Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021) (AIRS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01535118
First received: February 14, 2012
Last updated: June 9, 2014
Last verified: June 2014
  Purpose

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.


Condition
Allergic Rhinoconjunctivitis

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC) [ Time Frame: Within 12 months prior to survey ] [ Designated as safety issue: No ]
    Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.

  • Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months [ Time Frame: Within 12 months prior to survey ] [ Designated as safety issue: No ]
    Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated.

  • Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months [ Time Frame: Within 12 months prior to survey ] [ Designated as safety issue: No ]
    Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated.

  • Percentage of Participants Who Received Immunotherapy to Treat ARC [ Time Frame: Within 12 months prior to survey ] [ Designated as safety issue: No ]
    Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated.

  • Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication [ Time Frame: Within 12 months prior to survey ] [ Designated as safety issue: No ]
    Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated.


Secondary Outcome Measures:
  • Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma [ Time Frame: Within 12 months prior to survey ] [ Designated as safety issue: Yes ]
    Participants were asked about co-morbid health conditions. The percentage of participants who had received allergy shots to treat ARC and had asthma was calculated.


Enrollment: 2765
Study Start Date: January 2012
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Adults and Children with Allergic Rhinoconjunctivitis (ARC)
Adults and children with ARC who complete the survey

  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Adults and children with ARC in the United States.

Criteria

Inclusion Criteria:

  • Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies
  • 5 years of age or older
  • Have a telephone

Exclusion Criteria:

  • If less than 18 years old and there is no adult available that is knowledgeable about the participant's health
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01535118     History of Changes
Other Study ID Numbers: 7243-021
Study First Received: February 14, 2012
Results First Received: December 9, 2013
Last Updated: June 9, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Allergies
Immunotherapy

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

ClinicalTrials.gov processed this record on November 27, 2014